La Jolla Pharmaceutical Company Announces Preliminary GIAPREZA™ (Angiotensin II) Net Sales for the Three and Twelve Months Ended December 31, 2019
Jan 09, 2020
SAN DIEGO , Jan. 09, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced
